IQVIA
Category: AI in Healthcare
IQVIA is an American multinational company providing health information technology, clinical research services (CRO), and healthcare intelligence to the life sciences industry, powered by Healthcare-grade AI®. IQVIA was founded in 1982. The company is led by Ari Bousbib. Based in Durham, North Carolina, United States. Team size: 500+. Latest round: IPO. Key investors include Publicly traded on NYSE (IQV), Pre-IPO investors included TPG Capital, CPP Investment Board, Leonard Green & Partners (took IMS Health private in 2010).
- Founded
- 1982
- Headquarters
- Durham, North Carolina, United States
- Team size
- 500+
Value proposition
IQVIA combines the world's largest agnostic healthcare data assets (1.2B+ patient records) with Healthcare-grade AI® and deep domain expertise to accelerate clinical development, commercial effectiveness, and patient outcomes across the full life sciences value chain.
Products and solutions
IQVIA.ai (unified agentic AI platform, launched March 2026), CTFS GrantPlan (clinical trial budgeting), IQVIA Healthcare-grade AI®, Real World Evidence solutions, OCE/OCS (Omnichannel Engagement), MIDAS (global pharma market data), Clinical Trial Management, Pharmacovigilance, Regulatory Compliance solutions
Unique value
Healthcare-grade AI® — the only AI platform purpose-built for life sciences with regulatory compliance, 100+ AI-related patents, and access to 1.2 billion unique non-identified patient records globally.
Target customer
Pharmaceutical and biotechnology companies; medical device manufacturers; consumer health companies; payers and providers; government health agencies; financial institutions in healthcare
Industries served
Pharmaceuticals, Biotechnology, MedTech, Consumer Health, Healthcare Payers & Providers, Government/Public Health, Financial Services
Technology advantage
Largest agnostic healthcare data asset globally (1.2B+ patient records); 100+ AI-related patents filed; 150+ intelligent agents deployed; Healthcare-grade AI® with regulatory compliance built-in; NVIDIA AI Foundry partnership for custom foundation models; AWS preferred agentic cloud provider; 38M+ negotiated data points in CTFS GrantPlan
How they differentiate
IQVIA is uniquely positioned as the only company that combines a top-3 global CRO, the world's largest healthcare data and analytics platform, and Healthcare-grade AI® — creating an integrated data-to-insights-to-execution flywheel that pure-play CROs (LabCorp/Covance, Syneos) and pure-play data companies (Veeva, Definitive Healthcare) cannot match.
Main competitors
LabCorp/Covance (CRO), Medidata/Dassault Systèmes (clinical trial tech), Veeva Systems (life sciences cloud), Definitive Healthcare (healthcare data), Optum (healthcare analytics), Syneos Health (CRO)
Key partnerships
NVIDIA (strategic AI collaboration for IQVIA.ai, custom foundation models, agentic AI workflows), AWS (preferred agentic cloud provider, December 2025), Microsoft Azure (cloud infrastructure)
Notable customers
19 of the top 20 global pharmaceutical companies (including Johnson & Johnson, Pfizer, Novartis, Roche, Merck, Eli Lilly, AstraZeneca, among others)
Major milestones
1982: Founded as Quintiles by Dennis Gillings, 2010: IMS Health taken private by TPG/CPPIB/Leonard Green, 2016: Merger of Quintiles and IMS Health forming IQVIA, 2017: IPO on NYSE (IQV), 2025: Strategic AI collaboration with NVIDIA, 2025: AWS named preferred agentic cloud provider, 2026: Launch of IQVIA.ai unified agentic AI platform at NVIDIA GTC
Growth metrics
$16.3B revenue (2025); $15.4B revenue (2024); 5.87% YoY revenue growth; 93,000 employees (2025); Market cap ~$35B (2026); Fortune 500 (#282)
Market positioning
Global leader in healthcare data analytics and clinical research services. Ranked #282 on Fortune 500, #680 on Forbes Global 2000. Serves 19 of the top 20 pharmaceutical companies. $16.3B revenue (2025). 93,000 employees across 100+ countries.
Geographic focus
Global — operates in 100+ countries with strong presence in North America, Europe, and Asia Pacific
Patents and IP
100+ AI-related patents filed (as of March 2026); extensive patent portfolio in healthcare data analytics, clinical trial management, NLP, and AI/ML for life sciences
About Ari Bousbib
Ex-United Technologies Corporation (President & CEO of Otis Elevator, Chief Strategy & Development Officer); Ex-Booz Allen Hamilton (Partner); Managing Director at The Strategic Partners Group. Education: Columbia University (MBA), École Centrale Paris (Engineering degree).
Official website: https://www.iqvia.com